Vaccines and diagnostics—The case for regional One Health centres of excellence by Grace, Delia et al.
Vaccines and diagnostics—The case for regional One 
Health centres of excellence
One Health Colloquium: Sustainable livestock and disease control - exploring 
the links to climate change, improving human nutrition and the refugee crisis, 
London, 31 May – 1 June 2016
Delia Grace, Phil Toye, Shirley Tarawali and Vish Nene
Overview
• One health
– Definitions
– ILRI working in a OH paradigm
– OH addressing vaccine delivery and use
• Case studies
– East Coast Fever vaccine
– Newcastle disease vaccine 
– Diagnostics for TBD
• Conclusions
Health is “a state of complete physical, mental, and social well-being 
and not merely the absence of disease or infirmity” (World Health 
Organisation).
One Health "the collaborative effort of multiple disciplines —
working locally, nationally, and globally — to attain optimal health 
for people, animals and the environment” (One Health Commission).
Ecohealth “recognizes complex biophysical, social, cultural, political 
and economic relationships between the ecosystem and human 
health” (National Council for Science and the Environment).
Health and One Health
4Human 
health
Societies, cultures, 
Economies, institutions, 
Policies 
Agroecosystem 
health
Animal
Health
Vet 
Pub
Health
EcoHealth
One 
medicine
ONE HEALTH
Wildlife 
health
Plant health
International Livestock Research Institute
•a member of the CGIAR Consortium, ILRI conducts livestock, food and 
environmental research 
 to help alleviate poverty
 and improve food security, health & nutrition,  
 while protecting the natural resource base.
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International Livestock Research Institute
• Founded in 1974
• Budget: around US$80 million  
• Staff: 750: Senior scientists from 39 
countries: >half from developing 
countries
• 34% of internationally recruited staff 
are women --and 50% of the senior 
leadership team  
• Main campuses in Kenya and Ethiopia, 
and offices in 16 other countries 
around the world
ILRI experiences: Knowledge transfer, disease control and 
innovation in vaccines and diagnostics
• East Coast fever vaccine: ILRI involved development,
manufactured and transferred vaccine use to northern
Tanzania and manufacturing to CTTBD in Malawi
• Newcastle disease vaccine for village poultry: ACIAR
led development, widely promoted, recently evaluated
by ILRI in Tanzania
• Tick borne disease diagnostics: ILRI developed and
runs diagnostics
East Coast fever (ECF)
 ECF present in 12 countries; it could spread to 8 more
 Caused by a tick-transmitted protozoan – Theileria parva
 ~28 million cattle  at risk; ~1million deaths/year;  losses > 300 $ million a year
 Small-holder farmers who would benefit from control: ~ 20 million
 Not zoonotic: affects food supply, livelihoods, and vulnerable groups
Infection and treat method
Control milestones
• 1911-14: 283,000 cattle vaccinated in S. Africa, low 
success rate 
• 1911-1940: “T” brand oxen Kenya- exposed & immune
• 1980: DANIDA projects in Malawi, Zambia, Zimbabwe, 
Kenya
• 1983: Field use endorsed by FAO expert panel
• 1996: First commercial vaccine batch produced at 
ILRAD
• 2012: Authorized for dairy cattle in Kenya
• 2014: CTTB Malawi launched
• 2016: vaccine used Malawi, Kenya, Tanzania, Uganda
Research contributions
• 1928: Tick homogenates produce immunity and can be stored (Theiler & du Toit)
• 1953: OTC prevent reactions after vaccination  (Neitz in S Africa)
• 1954-57: Cocktail method developed in the Congo and Rwanda (Jezierski et al)
• 1973: Sporozoite stabilates (Cunningham in Kenya) 
• 1975: Muguga cocktail
• 1993: 30% solution
Donor investments
• 1967: UNDP funded tick program at EAVRO develops ITM: continues at KARI and ILRAD
• 1980: DANIDA projects in Malawi, Zambia, Zimbabwe, Kenya
• 1996: First commercial vaccine batch produced at ILRAD
• 2004: GALVmed founded – ECF a disease of focus
• 2014: CTTB Malawi launched
• 2016: vaccine used Malawi, Kenya, Tanzania, Uganda
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Success of ITM in Zambia and Tanzania
Since 1990s around 1.5 million cattle vaccinated – 1% of cattle at risk during that time
Most in Zambia and Tanzania
1982-2002 Belgian veterinary support project
• Local Katete strain
• Calf mortality reduced from 33% to 3%. Cost $10
• First year of charging: only 10% of farmers brought calves
2008-2014 IFAD project $15 million
• 300,000 vaccinated – around 20% of the at risk population
• Farmers pay 15% cost – revolving fund – unlikely to be sustainable
Success of ITM in Zambia and Tanzania
Since 1990s around 1.5 million cattle vaccinated – 1% of cattle at risk during that time
Most in Zambia and Tanzania
1995- 1998 ITTBD in Northern Tanzania
• 10-20,000 a year vaccinated
• Pastoral areas
2004-16 VetAgro private sector, 
• Around 80,000 a year, up to 80% of calves
• full cost recovery ($10 a calf)
• 2006 FAO subsidy, 2012-13 GALVMed, 2014 USAID
Transfer, impact and challenges
• MC produced on commercial basis by CTTBD
• GALVmed targets 2 million doses a year 
Technology
• Live vaccine
• Production demanding
• Breakthrough infections
• Liquid nitrogen cold chain
Delivery
• Relatively high cost $9-17
• Distribution has high financial risk
• Production and much delivery outside private sector
Newcastle disease
 Worldwide distribution; caused by virus; emergence potential
 Major poultry disease: 30-80% of village chickens die each year
 Minor zoonoses; impacts on livelihoods and food & nutrition security
 Strong gender dimension: most owned by women
 Epidemic disease and hence communal action important
History of Newcastle disease vaccination
• 1927 virus isolated from outbreak in Newcastle
• Spread rapidly in Asia and more slowly to rest of the world
• Second pandemic in late 1960s, devastated poultry industries
• Brought under control using live vaccines
• 1984 ACIAR started to fund research into ND in village poultry
• A new strain I-2 developed at the University of Queensland for village poultry
2003-2005 SANDCP project funded by Australia
• Mozambique, Malawi and Tanzania
• Participatory, gender-responsive, sustainable, approach
• Informed by one health thinking
• With support from production to end use and cost recovery
A one health approach to delivery
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Farmer knowledge and practice
EO: Farmers lie about diseased chicken to get 
them vaccinated….
I train the vaccinators on handling, giving 
injections, side affects
Vx: People complain about the 
amount charged….
3 out of 10 don’t pay…..
I have received no training…
Some sell vaccine to rich households and 
use water to vaccinate the birds of the poor 
households to make money
FGD: We are willing to pay 100 TSH 
(twice the price currently charged)
Wyatt et al., 2012
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Tick-borne diseases diagnostics
• Ticks and tick-borne disease 
• Important cattle disease; zoonotic potential
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ILRI diagnostics for ticks and tick-borne 
disease
• ELISA for: Theileria parva, Theileria mutans, Babesia bigemina, B. bovis, 
trypanosomes, Anaplasma marginale
• ELISA tests for 4 major TBDs  – developed ~ 20 years ago 
• Used mainly for resarch
• Anaplasma and Babesia tests offered commercially
• Point-of-care assays (lateral flow) for human trypanosomiasis (with FIND), 
cysticercosis (ASARECA) and PPR (Pirbright)
• Development proof of concept
• Business plan developed for cysticercosis tests but not funded
Use of tick borne diagnostics
• Explored commercial production but not viable
2012-2014
12,503
7,524
In house
External
Vaccines: good efficacy but (so far) less impact,
Dx: high impact factors, hard to attribute impacts
Conclusions
• Impact that scales:
• Vaccines intuitively enormously attractive
• Adoption by smallholders and pastoralists
challenging
• Evidence that counts:
• Insights into disease require investments into
infrastructure
This presentation is licensed for use under the Creative Commons Attribution 4.0 International Licence.
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